Please assess the completion status of the following clinical trial:

Trial Title: Pegylated Interferon and Ribavirin Therapy in Chronic Hepatitis Genotype 4

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:Adult males and females, 18 to 50 years of age; with documented chronic hepatitis C according to the following criteria: elevated serum alanine aminotransferase (ALT) above the upper limit of normal (40 U/l) on two occasions during the preceding six months; anti-HCV positive anti-body status assessed by second generation enzyme linked immunosorbent assay (Roche Diagnostics, Branchburg, New Jersey, USA); positive polymerase chain reaction for HCV RNA (Cobas Amplicor HCV Monitor v2.0; lower limit of quantitation 50 IU/mL); genotype 4; and criteria for chronic hepatitis C in liver biopsy performed within the preceding year with no signs of cirrhosis or bridging fibrosis on pretreatment liver biopsy.~-~Exclusion Criteria:~* Previous IFN-alpha therapy; other liver diseases such as hepatitis A, hepatitis B, schistosomiasis, autoimmune hepatitis, alcoholic liver disease, drug induced hepatitis, or decompensated liver disease; coinfection with schistosomiasis or human immunodeficiency virus; neutro¬penia (,1 500/mm3); thrombocytopenia (,90 000/mm3); creatinine concentration .1.5 times the upper limit of normal; serum a fetoprotein concentration .25 ng/ml; organ transplant; neoplastic disease; severe cardiac or pulmonary disease; unstable thyroid dysfunction; psychiatric disorder; current pregnancy or breast feeding; or therapy with immunomodulatory agents within the last six months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): 1. Pegylated IFN- alpha 2b~2. Ribavirin for 24 weeks (patients with RVR)
- 2 (Type: ACTIVE_COMPARATOR): 1. Pegylated IFN- alpha 2b~2. Ribavirin for 36 weeks (patients with complete EVR)
- 3 (Type: ACTIVE_COMPARATOR): 1. Pegylated IFN- alpha 2b~2. Ribavirin for 48 weeks (patients with partial EVR)
- 4 (Type: ACTIVE_COMPARATOR): 1. Pegylated IFN- alpha 2b~2. Ribavirin for 48 weeks (control)

Based on this trial design, predict the completion outcome and termination type (if applicable).